[go: up one dir, main page]

WO2007012661A8 - Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 - Google Patents

Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1

Info

Publication number
WO2007012661A8
WO2007012661A8 PCT/EP2006/064747 EP2006064747W WO2007012661A8 WO 2007012661 A8 WO2007012661 A8 WO 2007012661A8 EP 2006064747 W EP2006064747 W EP 2006064747W WO 2007012661 A8 WO2007012661 A8 WO 2007012661A8
Authority
WO
WIPO (PCT)
Prior art keywords
medicine
mchr
hydantoin
antagonists
derived compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/064747
Other languages
English (en)
Other versions
WO2007012661A1 (fr
Inventor
Fabrice Balavoine
Eric Nicolai
Eric Sartori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerep SA
Original Assignee
Cerep SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep SA filed Critical Cerep SA
Publication of WO2007012661A1 publication Critical patent/WO2007012661A1/fr
Publication of WO2007012661A8 publication Critical patent/WO2007012661A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les composés de formule générale (I) suivante dans laquelle : • Ar1, L1, R1, R2, R3, R4, R5, R6, L2, Q, et n sont tels que définis dans les revendications, ainsi que leur procédé de préparation. L'invention concerne également l'utilisation des composés de formule (I) en tant que médicament, et plus particulièrement pour la préparation d'un médicament destiné au traitement de l'obésité et des maladies associées, d'un médicament coupe-faim et/ou d'un médicament entraînant une perte de poids, d'un médicament destiné au traitement de la dépression et/ou de l'anxiété, et plus généralement d'un médicament destiné au traitement d'une maladie associée aux récepteurs MCH (mélanine concentrating hormone).
PCT/EP2006/064747 2005-07-28 2006-07-27 Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 Ceased WO2007012661A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508064 2005-07-28
FR0508064A FR2889189A1 (fr) 2005-07-28 2005-07-28 Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1

Publications (2)

Publication Number Publication Date
WO2007012661A1 WO2007012661A1 (fr) 2007-02-01
WO2007012661A8 true WO2007012661A8 (fr) 2007-03-29

Family

ID=36470939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/064747 Ceased WO2007012661A1 (fr) 2005-07-28 2006-07-27 Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1

Country Status (2)

Country Link
FR (1) FR2889189A1 (fr)
WO (1) WO2007012661A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
WO2009097998A1 (fr) * 2008-02-07 2009-08-13 Sanofi-Aventis Imidazolidine-2,4-diones substitués par un arylchalcogeno-arylalkyle, procédé de production, médicaments contenant ces composés et leur utilisation
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
KR101787309B1 (ko) * 2008-12-09 2017-10-18 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
CA2771278A1 (fr) 2009-08-26 2011-03-03 Sanofi Nouveaux hydrates de fluoroglycoside heteroaromatiques cristallins, substances pharmaceutiques comprenant ces composes et leur utilisation
CN101875636B (zh) * 2010-05-18 2012-01-04 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
WO2012077655A1 (fr) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Dérivé spiro présentant une activité agoniste de gpr119
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
CN102850252B (zh) * 2011-06-30 2014-08-13 山东大学 一种3,5,5’-三取代乙内酰脲的制备方法
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JP6624594B2 (ja) 2014-08-04 2019-12-25 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 炎症性、代謝性、腫瘍性および自己免疫疾患の処置に有用なピリミジンの任意選択により縮合されているヘテロシクリル置換誘導体
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107417669B (zh) * 2016-05-24 2021-07-06 中国医学科学院药物研究所 3-(1h-吲唑)-四氢嘧啶-2-酮类化合物、其制备方法及其用途
ES2749861T3 (es) 2016-06-13 2020-03-24 Borealis Ag Bandas sopladas por fusión de alta calidad con propiedades de barrera mejoradas
CA3079135A1 (fr) 2017-10-16 2019-04-25 Arturo Molina Anti-androgenes destines au traitement du cancer de la prostate resistant a la castration, non metastatique
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US20220306640A1 (en) * 2019-09-06 2022-09-29 Ono Pharmaceutical Co., Ltd. Hydantoin derivative
CN112759550A (zh) * 2019-11-04 2021-05-07 上海科技大学 一种平滑受体拮抗剂
CA3160508A1 (fr) 2019-12-20 2021-06-24 Nuevolution A/S Composes de ((((6-benzylamino-5-fluoropyrimidine-4-yl)amino)methyle)-piperidine-1-yl)acetamide substitues actifs a l'endroit des recepteurs nucleaires
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
EP4126875A1 (fr) 2020-03-31 2023-02-08 Nuevolution A/S Composés actifs vis-à-vis des récepteurs nucléaires
CA3174252A1 (fr) 2020-03-31 2021-10-07 Nuevolution A/S Composes actifs vis-a-vis des recepteurs nucleaires
KR102685058B1 (ko) * 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009741C3 (de) * 1970-03-03 1980-07-31 Bayer Ag, 5090 Leverkusen Aromatische Copolyamide
JP2004502690A (ja) * 2000-07-04 2004-01-29 ノボ　ノルディスク　アクティーゼルスカブ 酵素ｄｐｐ−ｉｖのインヒビターである複素環式化合物
WO2004009558A2 (fr) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108944B2 (en) 2010-02-16 2015-08-18 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US9481664B2 (en) 2010-02-16 2016-11-01 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2007012661A1 (fr) 2007-02-01
FR2889189A1 (fr) 2007-02-02

Similar Documents

Publication Publication Date Title
WO2007012661A8 (fr) Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
WO2007076260A3 (fr) Agonistes de recepteur de farnesoide x
DK1713475T3 (da) 1,3,5-trisubstituerede 4,5-dihydro-1H-pyrazol-derivater med CB1-antagonistisk aktivitet
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
PT1235787E (pt) Receptores agonistas beta2 adrenergicos
EA200501430A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EP1398029A8 (fr) Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
MX2008000255A (es) Activadores de urea glucocinasa.
WO2010011836A3 (fr) Traitement de divers troubles avec de la dihydroxy-7,8 flavone et ses dérivés
WO2010071783A8 (fr) Thiazoles en tant que ligands des récepteurs des cannabinoïdes
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
WO2006052889A3 (fr) Composes de quinolinone-carboxamide
DE60332663D1 (de) CCR1-Rezeptor-Antagonisten zur Behandlung u.a. Demyelinisierender entzündlicher Erkrankungen
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
MX2010003761A (es) Benzotiazoles como moduladores del receptor de grelina.
TW200503619A (en) Use of isoindolinone derivatives as insecticides
WO2005118549A3 (fr) Composes presentant une affinite pour le recepteur de la dopamine d3 et leurs utilisations
SE0402635D0 (sv) Chemical compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06778030

Country of ref document: EP

Kind code of ref document: A1